https://www.news-medical.net/news/20120905/Baxter-seeks-FDA-BLA-approval-for-BAX-326-rFIX-protein-to-treat-hemophilia-B.aspx
Baxter International Inc. today announced that the company has submitted a biologics license application to the United States Food and Drug Administration for...
baxterseeksfdablaapproval
https://www.ajmc.com/view/patient-reported-outcomes-favor-concizumab-prophylaxis-in-hemophilia-a-or-b
Analysis of the phase 3 explorer7 (NCT04083781) study indicates a preference for concizumab prophylaxis over no prophylaxis in patients with hemophilia A or B...
patient reported outcomesfavorconcizumabprophylaxishemophilia
https://www.ajmc.com/view/fda-approves-one-time-gene-therapy-fidanacogene-elaparvovec-for-hemophilia-b
The FDA has approved fidanacogene elaparvovec-dzkt (Beqvez; Pfizer), a gene therapy administered in a one-time dose, for certain patients with moderate to...
one timegene therapyfidanacogene elaparvovecfdahemophilia
https://www.idelvionhcp.com/home
Learn about IDELVION, the only rFIX therapy that provides powerful bleed protection, extended dosing, and high factor trough levels for patients with...
hemophilia bfactor ixtreatmentidelviontherapy
https://www.sharecare.com/blood/guide-managing-treating-hemophilia
Hemophilia B is a rare genetic bleeding disorder that causes low levels of a blood clotting protein called factor IX. In this guide, learn about treatment and...
hemophilia bguidetreatingmanaging
https://www.news-medical.net/news/20120605/Chatham-Baxter-partner-to-develop-and-commercialize-hemophilia-B-gene-therapy-treatment.aspx
Baxter International Inc. today announced that it has entered into an exclusive global agreement with Chatham Therapeutics, LLC, an affiliate of Asklepios...
hemophilia bchathambaxterpartnerdevelop